refine: updated data on navitoclax and ruxolitinib for myelofibrosis
Published 3 years ago • 241 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
2:12
refine: phase ii study of navitoclax ruxolitinib in jak inhibitor-naive patients with mf
-
1:18
novel approaches for the treatment of myelofibrosis: navitoclax ruxolitinib
-
8:03
phase ii trial of navitoclax and ruxolitinib in high-risk r/r myelofibrosis
-
1:52
an update on the use of navtemadlin in myelofibrosis
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
1:30
mdm2 inhibitors in myelofibrosis treatment: the addition of navtemadlin to ruxolitinib
-
3:13
therapies for patients who progress on jak inhibitors: imetelstat, navtemadlin, selinexor & tp-3654
-
1:46
ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
-
3:02
euplagia-1: phase i trial of glpg5201, a cd19 car-t product, in r/r cll and richter's transformation
-
26:11
installatin and operation video of full auto hematology analyzer/china care medical
-
20:26
3mensio ct pre-case planning: redo-tavr with prior sapien 3 (2 of 2)
-
4:39
imetelstat shows promise in advanced myelofibrosis
-
0:44
the recent fda approval of ponatinib for ph all following success in the phallcon trial
-
2:04
design and results of persist-1 trial of pacritinib for myelofibrosis
-
4:48
an insight into the management of cytopenias in mf
-
1:30
the use of pirtobrutinib in richter's transformation: data from the bruin trial
-
2:41
cell avidity as a predictor of t-cell efficacy
-
0:51
phase i study of copanlisib plus venetoclax in r/r dlbcl
-
2:20
quantifying the anemia benefit of momelotinib in mf: analysis of data from simplify-1 & simplify-2
-
3:10
the potential for early identification of relapse in dlbcl using serial ctdna sampling
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
1:44
the genomics of rt and prognostic implications of rt characterization